Thermo Fisher Scientific acquires viral vector business from Novasep for $875m

By PBR Staff Writer

Thermo Fisher Scientific announced the acquisition of Henogen, a Belgian viral vector manufacturing business belonging to Groupe Novasep, for about €725m ($875m) in cash.